Core Laboratories N.V. (CLB) Tops Q3 EPS by 1c; Raises FY11 EPS Outlook, Guides Q4
Core Laboratories N.V. (NYSE: CLB) reported Q3 EPS of $1.00, $0.01 better than the analyst estimate of $0.99. Revenue for the quarter came in at $231.34 million versus the consensus estimate of $238.07 million.
Core Laboratories N.V. sees Q4 2011 EPS of $1.06-$1.08, versus prior guidance of $252.24 and the consensus of $1.08. Core Laboratories N.V. sees Q4 2011 revenue of $240-$246 million.
Core Laboratories N.V. sees FY2011 EPS of $3.73-$3.75, versus prior guidance of $3.65-$3.72 and the consensus of $3.75. Core Laboratories N.V. sees FY2011 revenue of $904-$910 million, versus the consensus of $923.48 million.
Core Laboratories N.V. sees Q4 2011 EPS of $1.06-$1.08, versus prior guidance of $252.24 and the consensus of $1.08. Core Laboratories N.V. sees Q4 2011 revenue of $240-$246 million.
Core Laboratories N.V. sees FY2011 EPS of $3.73-$3.75, versus prior guidance of $3.65-$3.72 and the consensus of $3.75. Core Laboratories N.V. sees FY2011 revenue of $904-$910 million, versus the consensus of $923.48 million.